You are here
EpiPen fallout builds as adviser backs dumping Mylan board
MYLAN faces an increasing backlash over its handling of the EpiPen pricing controversy, as a top proxy adviser urged shareholders to oust the drugmaker's board.
Institutional Shareholder Services (ISS) said that the company's directors had failed to stop "significant
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org